Story
Bausch + Lomb Shares Rise After Q2 Revenue Beat, Raised Full-Year Guidance
Summary
The eye health company's stock is trading higher after it reported second-quarter revenue that surpassed analyst expectations and lifted its full-year 2026 sales forecast, citing significant improvements in profitability.
Bausch + Lomb (BLCO) shares climbed in pre-market trading after the eye health company announced second-quarter financial results that exceeded analyst forecasts and raised its revenue outlook for the full year, signaling growing momentum in its operational turnaround.
Q2 Earnings Beat and Upgraded Forecast
For the second quarter of 2026, Bausch + Lomb reported revenue of $1.39 billion, a 9% increase from the prior-year period and ahead of the consensus analyst estimate of $1.37 billion. The company's adjusted earnings per share (EPS) of $0.15 met market expectations.
Following the strong top-line performance, management raised its full-year 2026 revenue guidance. The company now projects revenue in a range of $5.44 billion to $5.54 billion, with the midpoint of that range now above prior analyst forecasts.
Profitability Turnaround Gains Steam
Beyond the headline figures, the company demonstrated a striking improvement in profitability. Operating income swung to a profit of $83 million, a significant reversal from an operating loss of $11 million reported in the second quarter of 2025.
AdThis operational strength was also reflected in cash generation and earnings. Key metrics included:
- Cash flow from operations: Surged to $153 million, up from just $35 million in the year-ago quarter.
- Adjusted EBITDA: Climbed by $50 million year-over-year to reach $241 million.
Market Reaction and Context
In pre-open trading, Bausch + Lomb stock rose 2.3%. The move stood in contrast to the broader U.S. equity market, where the S&P 500 was trading nearly flat, underscoring that the gains were driven by company-specific news.
Investor sentiment was already supported by a recent "Buy" rating initiation from UBS and a positive earnings season for many of Bausch + Lomb's sector peers. The combination of a revenue beat, an upwardly revised forecast, and a dramatic year-over-year improvement in profitability fueled investor confidence in the company's strategy.
Read next
More on Stocks
Summit Therapeutics Stock Soars on $2 Billion AstraZeneca Investment, Cancer Drug Collaboration
Summit Therapeutics shares surged over 20% after AstraZeneca announced a $2 billion strategic investment and a clinical collaboration to test combination cancer therapies, signaling strong confidence in Summit's lead drug candidate.
Hapag-Lloyd Stock Rallies After Second 2026 Profit Guidance Upgrade
Shares in the German shipping giant surged after it significantly raised its full-year earnings forecast for the second time, citing strong demand and favorable spot freight rates.
Smiths News Lifts FY2026 Forecast on Strong Collectables and World Cup Sales
The UK news wholesaler announced it expects full-year results to beat market expectations, driven by a record contribution from the FIFA World Cup and robust demand for collectables, sending its shares higher.
Vinci Shares Tumble to 52-Week Low on French Infrastructure Tax Proposal
Shares in French infrastructure giant Vinci fell sharply after the government proposed a new tax on transport concession operators, prompting analysts to warn of a significant hit to earnings.